A European startup is betting that drug companies big and small will look to outsource artificial intelligence expertise that can help design new protein-based medicines.
Cradle said Monday that it raised $24 million in Series A funding to refine its generative AI software for concocting new proteins or improving existing ones. And rather than building an internal pipeline of drug programs, Cradle is squarely a software-as-a-service company, CEO and co-founder Stef van Grieken told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.